We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Uropathogenic Bacteria Linked to Deadly Disease in Preterm Infants

By LabMedica International staff writers
Posted on 28 Mar 2016
Image: The application of metagenomic approaches to define the microbiota of the preterm infant gut and implicate uropathogenic Escherichia coli as a risk factor for necrotizing enterocolitis (NEC) and death (Photo courtesy of Chris Sternal-Johnson).
Image: The application of metagenomic approaches to define the microbiota of the preterm infant gut and implicate uropathogenic Escherichia coli as a risk factor for necrotizing enterocolitis (NEC) and death (Photo courtesy of Chris Sternal-Johnson).
Necrotizing enterocolitis (NEC) is an intestinal disease that afflicts about one in ten extremely premature infants and is fatal in nearly one-third of cases.

The premature infant gut is believed to react to colonizing bacteria, causing damage to the intestinal walls and severe infection. An association has been described between necrotizing enterocolitis and a subset of Escherichia coli bacteria, called uropathogenic E. coli (UPEC) that colonize the infant gut.

Scientists at the University of Massachusetts Medical School (Worcester, MA, USA) and their colleagues obtained stool samples from a cohort of 166 infants: 144 preterm and 22 that had been carried to term from hospitals in Cincinnati, Ohio, and Birmingham, Alabama. The team sequenced the infants' stool and developed metagenomic analysis tools to identify the bacteria colonizing each infant. Previous work had already identified Enterobacteriaceae, a family of bacteria that includes E. coli, as potentially associated with NEC.

The team singled out UPEC as the E. coli type most strongly linked to infants who developed NEC. In the study cohort, 27 of the infants developed NEC, all preterm. The disease was fatal in 15 of those cases. UPEC was found in 44% of the infants who developed NEC, compared to only 16% of the 111 infants who survived without developing NEC. Although the team did not address the question of where UPEC in an infant's gut might originate, they did observe an association between vaginal delivery and death from NEC in these extremely preterm infants. Metagenomic multilocus sequence typing analysis further defined NEC-associated strains as sequence types often associated with urinary tract infections, including ST69, ST73, ST95, ST127, ST131, and ST144.

Doyle V. Ward, PhD, a microbiologist and coauthor of the study, said, “Many infants do have UPEC in their gut. It may be that they're colonized when they pass through the birth canal, and this could be a source of risk. We just don't know yet. It's important to realize that infants also acquire many beneficial bacteria from their mothers during vaginal birth and it's likely that the good bacteria have a role in preventing NEC.” The study was published on March 15, 2016, in the journal Cell Reports.

Related Links:

University of Massachusetts Medical School


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Laboratory Software
ArtelWare

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more